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Abstract
Background: Studies of the pathogenic mechanisms underlying human myopathies and muscular dystrophies
often require animal models, but models of some human diseases are not yet available. Methods to promote the
engraftment and development of myogenic cells from individuals with such diseases in mice would accelerate
such studies and also provide a useful tool for testing therapeutics. Here, we investigate the ability of immortalized
human myogenic precursor cells (hMPCs) to form mature human myofibers following implantation into the
hindlimbs of non-obese diabetic-Rag1nullIL2rγnull (NOD-Rag)-immunodeficient mice.
Results: We report that hindlimbs of NOD-Rag mice that are X-irradiated, treated with cardiotoxin, and then
injected with immortalized control hMPCs or hMPCs from an individual with facioscapulohumeral muscular
dystrophy (FSHD) develop mature human myofibers. Furthermore, intermittent neuromuscular electrical stimulation
(iNMES) of the peroneal nerve of the engrafted limb enhances the development of mature fibers in the grafts
formed by both immortal cell lines. With control cells, iNMES increases the number and size of the human
myofibers that form and promotes closer fiber-to-fiber packing. The human myofibers in the graft are innervated,
fully differentiated, and minimally contaminated with murine myonuclei.
Conclusions: Our results indicate that control and FSHD human myofibers can form in mice engrafted with hMPCs
and that iNMES enhances engraftment and subsequent development of mature human muscle.
Keywords: Stem cell, Xenograft, Differentiation, Desmin, Lamin, Spectrin, Neuromuscular junction, Muscular
dystrophy, FSHD
Background
Muscular dystrophies afflict approximately 1 in 5000 in-
dividuals worldwide. Developing murine models to study
these diseases is essential in understanding the mecha-
nisms of pathogenesis and in testing potential therapies.
Animal models for some muscular dystrophies, such as
facioscapulohumeral muscular dystrophy (FSHD), are
still unavailable, however, and murine models of some mus-
cular dystrophies, whether naturally occurring or genetic-
ally engineered, are limited because they do not replicate all
the features of the human disease (reviewed in [1–4]). Mice
that carry human muscles from individuals with these dis-
eases would serve as more accurate models, reproducing
most, if not all, of the morphological, physiological, and
genomic features of the muscular dystrophies in man.
Two approaches have been tested to develop grafts of
human muscle tissues in mice. In one, the xenografts are
created by introducing small bundles of mature human
myofibers, obtained at biopsy, and suturing them to
muscles in immunodeficient mice [5]. Over time, some
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of these grafts survive and reform mature muscle tissue
that is largely human in origin, although they can also
contain significant numbers of murine myonuclei. The
myofibers in these grafts can be innervated by motor
neurons and supplied by capillaries that are murine in
origin, and they contract in response to electrical stimu-
lation. Although the mice carrying these human grafts
provide potentially excellent models, they would be diffi-
cult to generate in the numbers needed for therapeutic
testing.
As an alternative approach, several laboratories have
been investigating the ability of human myogenic cells to
develop into mature human muscle tissue in immunode-
ficient or dystrophic mice [6–11], reviewed in [12]. In
these studies, the endogenous murine muscle is typically
eliminated by freezing or injection of a toxin and, in
some cases, is prevented from regenerating by prior irradi-
ation. Human myoblasts are often tagged with luciferase
[13, 14], or green fluorescent protein (GFP) [15, 16], to en-
able them to be tracked by luminometric or fluorescence
methods after injection. In some studies, engrafted mice
have been exposed to different pharmacological agents,
such as Losartan [17], to alter angiotensin II signaling, or
a soluble form of the receptor for myostatin, ActRIIB-Fc
[18], to promote myogenesis and reduce fibrosis. These
treatments have improved the survival of the engrafted
human myogenic cells in mice and their differentiation
into myofibers, but the muscles they form are small and
therefore difficult to study by physiological, morpho-
logical, and genomic methods. Moreover, the engrafted
muscle tissue may also contain a large number of mur-
ine myonuclei, indicating that they are largely hybrid in
nature [18–20].
Here, we describe methods to generate xenografts in
mice of mature human myofibers from muscle precursor
cells, without significant murine contamination. We use
immunodeficient non-obese diabetic-Rag1nullIL2rγnull
(NOD-Rag) mice, which we first X-irradiate locally to
prevent regeneration of murine muscle and then treat
with cardiotoxin (CTX) to eliminate the murine tibialis
anterior (TA) muscle. We then inject an immortalized
clonal cell line of human myogenic precursor cells
(hMPCs) that express luciferase, enabling us to track the
developing graft over time (lox-hTERT hygromycin +
cdk4-neo (LHCN) cells [21]). We periodically subject
the engrafted leg to intermittent neuromuscular elec-
trical stimulation (iNMES) via the peroneal nerve. Elec-
trical stimulation has long been known to promote muscle
differentiation in vitro [22–24] and in vivo [25, 26], and
iNMES has been used therapeutically in man to promote
the recovery of skeletal muscle from injury [27–30]. We
report that iNMES significantly increases the number and
size of the human myofibers and improves the morph-
ology of the human skeletal muscle tissue in the grafts.
Many of the myofibers in the graft are similar to mature
murine myofibers in size, and they are both innervated by
motor neurons and fully differentiated. Moreover, they are
comprised almost exclusively of human myonuclei, with
minimal contamination by murine myonuclei. Initial stud-
ies of xenografts prepared with cells from an individual
with FSHD suggest that our methods can be also used
with dystrophic hMPCs. Thus, our results indicate that xe-
nografting of hMPCs into mice can generate human
muscle tissue with minimal contamination with murine
myonuclei and that iNMES promotes the formation and
development of the grafts.
Methods
Animals
Male NOD-Rag immunodeficient mice (strain NOD.Cg-
Rag1tm1Mom Il2rgtm1Wjl/SzJ; Jackson Laboratories,
Bar Harbor, ME) were used. These NOD-congenic mice
harbor the Rag1null mutation on chromosome 2 and the
IL2rγnull mutation on the X-chromosome which results
in the absence of T, B, and NK cells. NOD-Rag mice are
suitable for muscle xenografting, as they do not reject
transplanted myogenic cells, and they tolerate high levels
of irradiation [11, 31]. All protocols were approved by
the Institutional Animal Care and Use Committee of the
University of Maryland, Baltimore.
Cells
The immortalized hMPCs used in this study are described
in Zhu et al. [21]. They were generated by establishing pri-
mary hMPCs cultures by explant techniques from the pec-
toralis major muscle of a 41-year-old male Caucasian
heart transplant donor. Cells were immortalized by infec-
tion and selection with retroviruses containing expression
cassettes for CDK4 and neomycin resistance, or human
telomerase reverse transcriptase (hTERT) and hygromycin
resistance; the latter two flanked by Lox-P sites. From this
immortal population, a clone with robust myotube forma-
tion upon exposure to differentiation conditions in vitro
was selected. This cell line was initially named LHCN-M2
(for lox-hTERT hygromycin + cdk4-neomycin, myogenic
clone #2). Here, we refer to the cell line as “LHCN.” Cul-
ture conditions were as published [32]. We also used
hMPCs derived from the biceps muscle of an individual
with FSHD that were immortalized in an identical fashion.
These cells (15Abic) which we refer to as “FSHD” have
been described [32].
X-irradiation
The left hindlimbs of young adult mice (8 weeks old)
were subjected to a single, localized dose of X-
irradiation, as previously described [33]. This dose has
been previously shown to suppress >90 % of satellite cell
activation following CTX treatment [34]. Briefly, mice
Sakellariou et al. Skeletal Muscle  (2016) 6:4 Page 2 of 14
were anesthetized by an intraperitoneal injection of a 2:1
mixture of 80 mg/kg ketamine (Butler Schein Animal
Health, Dublin, OH) and 7 mg/kg xylazine (Akom,
Decatur, IL) and placed within a lead box. The left hind-
limb was extended through a hole in the box and exposed
to X-irradiation at a single dose of 25 Gy at ~2.5 Gy/min.
Ionizing radiation was delivered with a Pantak-Seifert
250KpV X-ray Irradiator (bipolar series model HF 320,
East Haven, CT). The radiation beam was focused onto
the lower hindlimb. Ion chamber dosimetry (PTW model
31006, Freiburg, Germany) was performed outside the
collimator to ensure delivery of the exact dosage to the
hindlimb, as well as inside the collimator (lead shielding),
to monitor backscatter of radiation.
CTX treatment and hMPC transplantation
Mice were anesthetized with 2–2.5 % isoflurane. A solu-
tion of 0.3 mg/ml CTX (Naja mossambica mossambica;
Sigma-Aldrich, St. Louis, MO) was prepared in sterile
phosphate-buffered saline (1× PBS, 0.02 % sodium azide)
and sterilized by filtration (0.2 μm filter, PALL Corpor-
ation; Port Washington, NY). The CTX solution was
loaded into a 300-μl tuberculin syringe with a 29-gauge
needle (Terumo, Elkton, MD) and injected to a final
dose of 2 μg/mg body weight, distributed to three sites
along the length of the host TA muscle. CTX injection
induces selective degeneration of endogenous myofibers
without affecting the blood vessels or nerves [35, 36].
CTX injections were performed 24 h before hMPC
transplantation, as pilot studies suggested that injecting
cells at later times following CTX treatment resulted in
poorer engraftment. Immediately prior to transplant-
ation, hMPCs were released from the substrate by brief
digestion with trypsin, diluted in an equal volume of
growth media, and subjected to centrifugation at 1 ×
103 rpm for 3 min (IEC Centra CL2 centrifuge, Thermo
Scientific). Cells were suspended in 50 μl growth media
and injected into the TA compartment along the length
of the tibia to promote broad distribution of the injected
hMPCs. For studies of LHCN cell engraftment, aliquots
of cell suspensions containing 5 × 105 (group 1, n = 18)
or 2 × 106 (group 2, n = 25) hMPCs were injected and
monitored over time, with no further treatment. An add-
itional experimental group was injected with 2 × 106
hMPCs and subjected to intermittent neuromuscular
electrical stimulation (group 3, n = 23), as described
below. For studies of FSHD cell engraftment, only ali-
quots of 2 × 106 cells were used, with six mice treated
with iNMES and six controls.
Bioluminescence imaging
Bioluminescence imaging (BLI) was performed with a
Xenogen IVIS® 200 system (Perkin Elmer, Hanover, MD)
to monitor the survival and development of the
engrafted hMPCs non-invasively. Mice were anesthe-
tized with 2–2.5 % isoflurane. A solution of D-luciferin
(40 mg/ml) (Caliper Life Sciences, Hopkinton, MA) was
prepared in sterile PBS and sterilized by filtration
(0.2 μm filter; PALL Corporation). Mice were injected
intraperitoneally (IP) with D-luciferin at 150 mg/kg and
returned to their cages for 5 min to allow the compound
to distribute through the body. Anesthetized mice were
placed in the Xenogen IVIS chamber to measure the
light emitted as a result of the action of luciferase on D-
luciferin. Imaging was performed 15 min after D-luciferin
injection, when the luciferase activity reached its peak,
based on previously acquired studies of the luciferase sig-
nal (60 min sequence, imaging for 1 min at 5 min inter-
vals). In total, 16 mice injected with LHCN cells were
used for assessing the intensity of the bioluminescence
signal at 2 h (day 0) and at 7 and 28 days after transplant-
ation. To estimate the loss of transplanted hMPCs over
longer time periods, five of these 16 mice were scanned
on a weekly basis for up to 7 weeks (group 1 = 3 mice,
group 2 = 1 mouse, and group 3 = 1 mouse). Regions of
interest (ROI) within the injected region were selected,
and the light generated by luciferase was quantified as
photon flux (photons/second) with Living Image® 4.3.1
software (Perkin Elmer). The bioluminescence image,
shown in pseudocolor, is overlaid on a photographic
image of the mouse, with intensity represented from blue
to red, representing least to most bright.
Intermittent neuromuscular electrical stimulation
iNMES was initiated on day 5 after initial transplant-
ation. Mice were anesthetized with 2–2.5 % isoflurane.
The ankle dorsiflexors of the injected hindlimb were
stimulated electrically through the intact skin over the
common peroneal nerve, with the electrode placed over
the head of the fibula. Monophasic square wave pulses,
0.1 ms in duration, were delivered to the stimulation
electrode by an S48 Stimulator (Grass Instruments,
Warwick, RI). A stimulation isolation unit (model
PSIU6; Grass Instrument) was used to minimize artifact
and to ensure that the peak current delivered was no
greater than 15 mA. The iNMES training protocol con-
sisted of four sets of ten contractions. Each contraction
lasted 500 ms (150 Hz pulse frequency), followed by a
500-ms rest. Rest times of 2 min were allowed between
each set of contractions to minimize the effect of fatigue.
iNMES training was performed three times/week for
4 weeks. Most samples were analyzed between 4 and
5 weeks after injection of hMPCs.
Antibodies, immunofluorescence labeling, imaging, and
morphometry
Mice under isoflurane anesthesia were euthanized by
cervical dislocation. Muscle in the engrafted region was
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removed, weighed, and embedded in O.C.T. (Tissue Tek;
Torrance, CA), snap frozen in a slush of liquid N2 and
stored at −80 °C. Serial frozen cross sections (10–15 μm
thick) were cut and mounted on glass Superfrost micro-
slides (VWR, Radnor, PA).
Immunolabeling was performed on unfixed cross sec-
tions from every TA muscle sample to visualize the pres-
ence of human proteins in the graft. Mouse monoclonal
antibody specific for human β-spectrin (1:50; Leica, Buffalo
Grove, IL) was routinely used to label the sarcolemma. In
some studies, mouse monoclonal antibody to human
lamin A/C (1:200; Leica) were used to label the nuclear
lamina. To evaluate the internal organization of the newly
formed human myofibers, sections were also stained with
a rabbit polyclonal antibody to desmin (1:100; Thermo
Scientific).
For immunolabeling with mouse monoclonal anti-
bodies, the “mouse-on-mouse” (MOM) kit from Vector
Laboratories (Burlingame, CA) was used to reduce non-
specific staining. Briefly, sections were incubated for 1 h
with MOM Ig blocking reagent and then for 10 min
with MOM diluent solution (1:80 dilution of protein
concentrate in PBS). Slides were incubated overnight at
4 °C with primary antibodies diluted in MOM diluent
solution, washed three times with PBS, and incubated
with Alexa Fluor 488-conjugated goat anti-mouse IgG
(H + L) and Alexa Fluor 568-conjugated goat anti-rabbit
IgG (H + L) (1:200; Molecular Probes, Life Technologies,
Grand Island, NY) for 1–2 h at RT. Sections were
washed three times with PBS and mounted in Vecta-
Shield containing 4′,6-diamidine-2′-phenylindole dihy-
drochloride (DAPI; Vector Laboratories). For sections in
which monoclonal anti-spectrin and polyclonal rabbit
anti-desmin were used, we followed similar procedures
but incubated the sections in Alexa Fluor 488-
conjugated goat anti-mouse IgG (H + L) and Alexa Fluor
633-conjugated goat anti-rabbit IgG (H + L) (1:200; Mo-
lecular Probes).
Samples were viewed with a Zeiss LSM5 DUO con-
focal microscope, with 40× or 63× objectives (Carl Zeiss,
Jena, Germany) and the pinhole set at 1 Airy unit. Images
were analyzed with LSM Image software (Carl Zeiss).
Myofibers of human origin, identified by labeling of the
sarcolemma with antibodies against human β-spectrin
(see above), were counted.
Minimum Feret’s diameter, a measure of the size of
myofibers, was determined for grafts generated with
LHCN cells, as described [37]. Engrafted myofibers were
divided into three groups according to size (1–9, 10–19,
and ≥20 μm). For each graft, the percentage of myofibers
within each group was calculated and compared between
groups. Distances from the largest human myofibers in
the graft to their nearest neighbors were also measured.
Additional morphometric measurements included the
number of human lamin A/C-positive nuclei in the
grafts, identified by labeling with antibodies to human
lamin A/C [6–8, 10, 11, 38–43], the number of murine
myonuclei in myofibers of human origin, identified as
myonuclei labeled by DAPI but not by antibodies to hu-
man lamin A/C, and the number of centrally nucleated
human and murine myofibers.
For labeling of the neuromuscular junction in grafts
formed by LHCN cells, sections were fixed with 4 %
paraformaldehyde, washed three times with TBS and in-
cubated with TBS + 0.25 % Triton X-100 for 10 min.
Sections were incubated with antibody dilution buffer
(PBS + 5 % goat serum, 1 % BSA, 0.1 % fish skin gelatin,
and 0.05 % azide), followed by overnight incubation with
mouse monoclonal antibodies to synaptophysin (1:100
DAKO M7315) and human β-spectrin. After washing,
samples were incubated for 1–2 h at RT with Alexa
Fluor 488-conjugated goat anti-mouse IgG1, for synap-
tophysin, and Alexa Fluor 568-conjugated goat anti-
mouse Ig2B for β-spectrin, as well as Alexa Fluor 633-α-
bungarotoxin (all from Molecular Probes). Secondary
antibodies and α-bungarotoxin were diluted to 1:500
and 1:200, respectively. Sections were washed three
times with PBS and mounted in VectaShield containing
DAPI.
Statistical analysis
Statistical comparison of the number of fibers in the dif-
ferent groups of xenografts used the t test. The sizes of
the engrafted human myofibers across the experimental
groups were analyzed with the chi-square test. The
intermyofiber distance between the largest engrafted
myofibers and their closest neighboring myofibers was
evaluated with the Fisher exact test. Since the sample
size for our BLI data was small, we used bootstrapping
to evaluate the results [44]. Data are presented as the
mean ± standard deviation (SD). A p value of <0.05 was
considered to be statistically significant.
Results
In vivo bioluminescence imaging reveals acute donor cell
loss within the first week following transplantation
We initially used BLI to evaluate the efficiency of en-
graftment and the survival of engrafted LHCN cells. We
acquired luminometry images for most mice on day 0, at
about 2 h after injection of the hMPCs, and then at 7
and 28 days after transplantation. We also examined
some mice on a weekly basis for up to 7 weeks post-
engraftment (Fig. 1a). Injection of 5 × 105 (group 1) or
2 × 106 hMPCs (groups 2 and 3) into the X-irradiated
and CTX-intoxicated murine TA compartment resulted
in a robust bioluminescence signal at day 0 of injection.
We observed a significant decay in the bioluminescent in-
tensity for all three experimental groups, indicating <10 %
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average retention of hMPCs after 1 week post-
transplantation. A gradual reduction in the biolumin-
escent intensity was observed thereafter, with results at
4 and 7 weeks corresponding to average cell survival
rates of 6 and 3 %, respectively (Fig. 1b). No differences
were observed in the signals obtained from the grafts
between 7 and 28 days post-injection for groups 2 and
3 (two-tailed test; p = 0.38 and p = 0.34, respectively).
Overall, our data indicate that the vast majority of
injected hMPCs failed to survive under each of the
conditions tested.
iNMES promotes hMPC engraftment and maturation
We collected the tissues formed by the engrafted LHCN
cells at 4 to 5 weeks after transplantation and character-
ized them. We first compared the mass of the engrafted
muscle with that of control mouse TA muscles. The
grafts, which included the tissue formed by the injected
hMPCs as well as connective tissue and any remaining
murine tissue that resisted CTX intoxication, varied
from 4 to 14 mg in mass (mean ± SD, 9.9 ± 6.1 for group
1; 9.1 ± 2.7 for group 2, without iNMES; 12.5 ± 11.6 for
group 3, with iNMES). By contrast, TA muscles in
healthy mice have a mass of 31–51 mg (mean ± SD,
43.3 ± 2.8 mg). Thus, the yield of tissue in the grafts
is too variable for any differences to reach statistical
significance.
To examine the nature of the tissues in the grafts
formed by the LHCN cells, we prepared frozen cross
sections and labeled them by immunofluorescence
methods with antibodies specific for human β-spectrin,
a protein present at the sarcolemma of mature myofibers
[45]. As shown in Fig. 2, the anterior tibial compartment
of the hindlimb, formerly occupied by the murine TA
muscle, contains tissue of human origin, as it stains with
the antibody specific for human β-spectrin (green in
Fig. 2). These cells also label for desmin (red in Fig. 2),
an intermediate filament protein expressed only in
muscle [46–49], indicating that the cells positive for β-
spectrin at the sarcolemma are indeed muscle fibers of
human origin. No fibers in this region fail to stain with
the antibody to human β-spectrin, suggesting that all are
generated at least in part by the fusion of hMPCs to
form myofibers. By contrast, murine myofibers, identi-
fied by labeling for desmin but not for human β-
spectrin, are apparent in regions of the hindlimb that
were not exposed to CTX. Our results indicate that
transplantation of hMPCs into murine hindlimb exposed
to X-irradiation and CTX can yield muscle tissue of hu-
man origin.
Quantitation of the results of grafts formed after injec-
tion of 5 × 105 LHCN cells revealed that only one of 18
engrafted limbs (~6 %) developed muscle fibers of hu-
man origin. By contrast, approximately 50 and 75 % of
limbs injected with 2 × 106 LHCN hMPCs developed
muscle fibers of human origin under control conditions
and following iNMES, respectively (Fig. 3; Table 1).
These differences were significant (p < 0.05).
We used three additional morphological criteria—
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Fig. 1 Monitoring of hMPCs after transplantation. a Representative bioluminescence images of mice on days 0, 7, 28, and 49 post-transplantation
with 2 × 106 hMPCs and a 4–5-week period of iNMES training (n = 4). Signal activity was detected in the regions of interest (ROI), encompassing
the TA where the cells were originally injected, and quantified as photons/s. b Quantitative analysis of bioluminescence as a function of time
following transplantation. Within the first week post-transplantation, <10 % of the original signal was detected in each of the three groups
analyzed (group 1, N = 3; group 2, N = 7; group 3, N = 6). Less than 5 % of the transplanted hMPCs were retained at the end of the 7-week period
following transplantation
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spacing—to assess the human muscle tissue in the
LHCN xenografts. Quantitation of the number of
muscle fibers of human origin in the graft, identified
by immunofluorescence labeling with antibodies to hu-
man β-spectrin, shows that more large fibers formed
following injection of 2 × 106 hMPCs and treatment
with iNMES than under the two other conditions we
tested. In the one graft that formed from LHCN cells
injected at a dose of 5 × 105, 22 of the 33 myofibers
present in the graft were <10 μm in diameter, while
33 % reached diameters of 10–19 μm (11/33, Fig. 4).
The grafts formed in group 2, injected with 2 × 106
LHCN hMPCs but not exposed to iNMES, contained
more muscle fibers of larger size, ranging in number from
13 to 145 per graft (Fig. 3), with nearly half (128 of 267 or
48 %) being >10 μm in diameter (Fig. 4). These results
suggest that increasing the number of injected hMPCs
from 5 × 105 to 2 × 106 promotes successful engraftment
and muscle development (p < 0.01).
Injection of 2 × 106 LHCN hMPCs followed by iNMES
led to grafts with the highest numbers of human muscle
fibers of the largest size (Table 1). Mice in this group
developed grafts containing 76.9 ± 77.9 (mean ± SD) hu-
man myofibers, compared to 31.8 ± 45.0 in group 2 (p <
0.05). The human myofibers in the grafts of group 3
were also larger, with 52 % reaching diameters of 10–
19 μm diameter, and 21 % reaching diameters of ≥20 μm
(Fig. 4). The largest number of myofibers of human ori-
gin in grafts exposed to iNMES was 226, ~10 % of the
number of myofibers in a normal mouse TA muscle
[50]. At 4–5 weeks after transplantation of LHCN cells,
we observed differences in the distribution of myofiber
sizes between groups 2 and 3, with grafts in group 3
containing a higher percentage of larger myofibers
≥20 μm in size and a smaller percentage of myofibers of
1–9 μm in size (22 % large, 27 % small) compared with
group 2 (15 % large, 37 % small; p < 0.00001). Therefore,
iNMES not only promotes the success of engraftment
but also increases the number and size of the human
muscle fibers formed by the engrafted hMPCs.
We further evaluated the integrity of the human
muscle tissue in the grafts formed by the LHCN hMPCs
by measuring the distances from the largest myofibers of
human origin in groups 2 and 3 to their nearest














Fig. 2 Grafts formed by 2 × 106 hMPCs with and without iNMES. The presence of human muscle fibers in murine hindlimbs was evaluated at
4 weeks post-transplantation. An antibody specific for human β-spectrin was used to stain cross sections of grafts by immunofluorescence;
antibodies to desmin were used to stain both murine and human muscle fibers. The results show more human β-spectrin-positive myofibers
(green), of larger size and in denser packing, in the grafts of mice treated with iNMES (group 3; B1, B4, B5) compared with untreated mice (group 2; A1,
A4, A5). White arrows in A1 and A2 indicate a region of endogenous murine muscle that persisted following X-irradiation and CTX treatments. All cells
labeled with antibodies to human β-spectrin in both groups 2 and 3 labeled with antibodies to desmin (red in merged images, A2 and B2, respectively),
confirming their identity as myofibers. A3 and B3 show the boxed areas in A2 and B2 at higher magnification. A4 and A5, and B4 and B5, show muscle
fibers of human regions of two other grafts from mice treated without (A4, A5) and with (B4, B5) iNMES. Scale bars = 50 μm
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neighbors. Our results show that the largest myofibers
in group 3 are closer to their nearest neighbors (4.2 ±
4.2 μm) than those in group 2 (7.6 ± 5.6 μm; p < 0.0001),
consistent with the larger number of myofibers in these
grafts and their closer packing (Fig. 5; Table 1).
We addressed the state of differentiation of the human
muscle fibers in the grafts formed by LHCN cells in
groups 2 and 3 by examining cross sections of the
engrafted tissues labeled with antibodies to desmin. Our
results indicate that nearly all the larger myofibers of hu-
man origin in groups 2 and 3 have a reticulum of des-
min in the myoplasm (Fig. 6a, b), formed as desmin
aligns with myofibrils as they striate (Fig. 6c). Desmin
normally assembles into a filamentous reticulum around
the Z-disks at the later stages of assembly of the con-
tractile apparatus, as the process of differentiation into
myofibers is completed [46, 48, 51]. The presence of a
striated reticulum of desmin in the larger human muscle
fibers in the grafts therefore suggests that these cells
have undergone terminal differentiation.
Nuclear labeling with DAPI provided an additional
method to determine if engrafted muscle fibers of hu-
man origin were terminally differentiated. In developing
or regenerating muscle tissue, nuclei are frequently
found in the middle of the cell, whereas in healthy, fully
differentiated human muscle tissue (but not in regener-
ated mouse muscle), nearly all of the myonuclei are
located peripherally, immediately adjacent to the sarco-
lemma. Evaluation of human myofibers in the grafts
formed by LHCN cells, co-labeled with antibodies spe-
cific for human lamin A/C, showed that only 17.5 (36/
205) and 13.7 % (69/505) had central nuclei of human
origin in groups 2 and 3, respectively. (Murine myonu-
clei comprised <1.5 % of all central myonuclei in fibers
positive for human β-spectrin and so did not contribute
significantly to the population of central nuclei: see
below). Thus, grafts in both groups 2 and 3 likely con-
sisted of a mixed population of fully and partially differ-
entiated myofibers of human origin, with >80 % being
fully differentiated. Overall, our results suggest that most
of the grafts formed by engrafted LHCN hMPCs differ-
entiate into mature human muscle fibers during the 4 to
5-week period post-transplantation, and that, although
the formation, growth, and maturation of the grafts are
promoted by iNMES, iNMES is not required for
differentiation.
The presence of large, differentiated myofibers in the
grafts suggests that the myofibers formed by the LHCN
hMPCS are innervated. In the absence of innervation,
these fibers would atrophy significantly and would con-
sequently be reduced in size [52]. To test for innerv-
ation, we labeled the grafts of group 3 with a fluorescent
derivative of α-bungarotoxin to detect the large clusters
of acetylcholine receptors (AChRs) in the postsynaptic
membrane of the neuromuscular junction. We found
clustered AChRs, suggesting that innervation had oc-
curred within 4 weeks after transplantation of hMPCs
(Fig. 7). As the AChRs of non-innervated muscle cells
can also aggregate [53, 54], we also immunolabeled
Table 1 Properties of xenografts
Group 1 Group 2 Group 3
Number of hMPCs injected 5 × 105 2 × 106 2 × 106 + iNMES
Mice (number) 18 24 23
Mice with human fibers (%) 6 48 74
Average number of human fibers/grafta 2.2 ± 8.9 31.8 ± 45.0 76.9 ± 77.9
Minimum Feret’s diameter (μm)a 8.6 ± 3.4 12.4 ± 7.1 13.5 ± 6.3




















Group 1 Group 2 Group 3
**
*#
Fig. 3 Number of human myofibers per xenograft. The scattergram
shows the distribution of the total number of engrafted human
muscle fibers in each graft following hMPC transplantation,
determined by counting the number of fibers labeled with
antibodies to human β-spectrin in cross sections. Only one graft
with human tissue, containing 39 human myofibers, was obtained
from a total of 18 mice in group 1. Groups 2 and 3 showed more
grafts with higher numbers of muscle fibers of human origin, with a
range of 13–145 and 22–226 myofibers per cross section sampled,
respectively. Differences between groups were significant by t tests
(#p < 0.01; *p < 0.05; **p < 0.001)
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sections with antibodies to synaptophysin, a protein lo-
calized presynaptically at motor nerve terminals [55, 56].
Immunostaining for synaptophysin was faint but present
adjacent to the clusters of AChRs on the surface of the
human myofibers in the graft (Fig. 7b), indicative of an
intact neuromuscular junction. We conclude that human
myofibers in the grafts formed by LHCN cells are indeed
innervated.
We next considered the possibility that a small num-
ber of endogenous murine satellite cells might have
resisted X-irradiation and could therefore have expanded
and fused with the transplanted hMPCs following CTX
intoxification, leading to the formation of hybrid murine-
human myofibers. In the absence of a mouse-specific
lamin A/C antibody, we identified murine myonuclei as





















1 to 9 microns
10 to19microns
> 20microns
Group 1 Group 2 Group 3
Fig. 4 Size distribution of human muscle fibers cells in the xenografts. Minimum Feret’s diameters of the human muscle fibers were measured.
Values were binned (1–9, 10–19, and ≥20 μm), and each bin was expressed as percent of the total. Significantly more (21 %) human muscle fiber
in the mice of group 3 reached larger sizes (>20 μm) compared with those detected in mice from groups 1 and 2 (0 and 15 %, respectively) (chi-


























2 to 5 microns
> 5 microns
Group 2 Group 3
Fig. 5 Nearest neighbor distances of the human muscle fibers in the grafts. Distances between the largest muscle fibers of human origin in
groups 2 and 3, and their nearest neighbors were measured and binned in three groups (<2, 2–5, and >5 μm). Each bin was expressed as
percent of the total. The histograms show the distribution of distances between neighboring human muscle fibers. Human myofibers in the
grafts in group 3 were more closely spaced than those in group 2 (Fisher’s exact test, p < 0.0001)
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labeled positively for human β-spectrin but that failed to
label with antibodies specific for human lamin A/C [6–8,
38, 41–43]. Images of sections of a graft labeled with anti-
bodies specific for human β-spectrin and human lamin A/
C, and counterstained with DAPI to visualize nuclei, are
shown at both low and high magnification in Fig. 8. Quan-
titation of central nuclei of murine origin in human myofi-
bers showed that their numbers were extremely low both
in group 2 (2/205, or 1 %) and group 3 (7/505, or 1.4 %).
Nearly all myonuclei are centrally located in murine mus-
cles at 4 weeks after CTX intoxication, however. Thus, our
results indicate that there was minimal murine contamin-
ation of the human myofibers formed by LHCN hMPCS.
Consistent with these results, qualitative assessment of
the human muscle grafts formed by LHCN hMPCs
across the three experimental groups revealed that the
vast majority of the murine myofibers were ablated
following X-irradiation and CTX treatment. Those
remaining were typically at the edge of the graft contain-
ing human muscle tissue, indicating that the human
muscle and murine muscle tended to segregate from
one another spatially. Therefore, the combination of X-
irradiation and CTX treatments of the murine TA
muscle not only eliminated all or nearly all of the tissue
of murine origin but also inhibited the formation of hy-
brid human-murine myofibers.
Finally, we performed preliminary studies to determine
if the methods we had developed for LHCN cells could
be applied to an immortalized human myogenic cell line
derived from an individual with FSHD. As shown in
untreated
5 µm 5 µm
human spectrin
desmin







Fig. 6 Reticulum of desmin in muscle fibers of human origin. Unfixed cross sections of the xenografts of groups 2 and 3 were labeled with
antibodies to desmin (a, b). The reticular pattern of staining for desmin (red) in the myoplasm of human myofibers (white arrowheads), identified
by the presence of human β-spectrin (green) at the sarcolemma, indicates that the larger myofibers in both groups 2 (a) and 3 (b) are fully
differentiated. c A fiber from group 3 with desmin in striations, indicating that the reticulum of desmin is fully organized around myofibrils.
Scale bars = 5 μm
BA
5 µm 5 µm
synaptophysin
human spectrin human spectrin
Fig. 7 Neuromuscular junctions in the xenografts. Cross sections of unfixed xenografts from group 3 were labeled with Alexa Fluor
633-α-bungarotoxin to visualize postsynaptic acetylcholine receptors (AChRs) (blue; a, b, arrows) and with antibodies to human β-spectrin (red; a, b)
and to synaptophysin (green; b, arrowhead) to visualize the sarcolemma of human myofibers and presynaptic structures, respectively. The results show
the accumulation of AChRs at the sarcolemma of human myofibers (a, b; arrows) that correspond with sites of innervation (b; arrowhead).
Scale bars = 5 μm
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Fig. 9a, engraftment of FSHD hMPCs leads to the for-
mation of muscle tissue that has large fibers of human
origin. Figure 9b shows that exposure of the grafts to
iNMES also significantly increases the sizes of the grafts
formed by FSHD hMPCs (p < 0.01). Thus, our methods
can indeed be applied to other immortalized lines of
hMPCS, including those from individuals with muscular
dystrophies.
Discussion
Previous studies of grafts of hMPCs into immunodefi-
cient or dystrophic murine muscle have shown that the
regenerative potential of the endogenous muscle cell
population typically is only partially eliminated, leading
to the formation of hybrid human-murine myofibers and
hence the expression of both human and murine muscle
proteins. The purpose of our study was to discover if
suppressing the myogenic potential in the hindlimb of
the host mouse would permit muscle fibers to form that
are largely, if not exclusively, human in origin. Our ul-
timate goal was to develop mature skeletal muscle tissue
in the murine hindlimb consisting exclusively of human
myofibers, with few or no murine myonuclei. We used a
dose of X-rays sufficient to block myogenesis in immu-
nodeficient NOD-Rag mice (25 Gy), followed by injection
of the myotoxin CTX to eliminate their TA muscles. We
then injected the TA compartment with hMPCs express-
ing luciferase (LHCN cells [21]). Our results indicate that
hMPCs do indeed generate mature innervated, human
myofibers in mice treated in this way. They also show that
contamination of the human fibers with murine myonu-
clei is minimal (<1.5 %) and that iNMES promotes the
survival and development of human myofibers formed by
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Fig. 8 Centrally located myonuclei of human and murine origin in xenografts. Unfixed cross sections were immunolabeled with antibodies to
human β-spectrin (green) and human lamin A/C (red) and counterstained with DAPI (blue) to label all nuclei. Human myonuclei, positive for DAPI
and human lamin A/C, and murine myonuclei, positive for DAPI but not for human lamin A/C, were quantitated in human myofibers and identified by
the presence of β-spectrin at the sarcolemma. Images of human myofibers in group 2 (a, b) and group 3 (c, d) show labeling for spectrin and lamin
A/C (a, c) and for both proteins and DAPI (b, d). a, b Arrows point to myofibers with nuclei labeled with antibodies to human lamin A/C. Arrowheads
point to nuclei labeled with antibodies to human lamin A/C lying outside of muscle fibers. c, d Arrow points to a human myofiber with a nucleus that
is unlabeled by antibodies to human lamin A/C. Arrowheads point to nuclei that lie outside of muscle fibers and that do not label with antibodies to
human lamin A/C. e High magnification examples of human fibers with a myonucleus that labels with anti-human lamin A/C (E1), a nucleus lying
outside a human fiber that labels with anti-human lamin A/C (E2), a human fiber with a myonucleus that fails to label for human lamin A/C (E3), and a
nucleus that fails to label for human lamin A/C lying outside a human fiber (E4). f Percent of centrally located human and murine myonuclei detected
in human muscle fibers in groups 2 and 3 at 4–5-weeks post-transplantation. Of the human fibers examined, <20 % was centrally nucleated
(group 2 = 36/205, or 17.5 %; group 3 = 69/505 or 13.7 %). Only 2 myonuclei out of 205 (1 %) in group 2 and 7 myonuclei out of 505 (1.4 %) in
group 3 failed to label with antibodies to human lamin A/C. Scale bars = 10 μm
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dystrophic muscle. To our knowledge, ours are the first
results to demonstrate that human myofibers can be gen-
erated in mice without the incorporation of significant
numbers of murine myonuclei. They further establish that
our methods can generate human muscle tissue in mice
from hMPCs from an individual with FSHD.
Although our results are unique, our methods are
based on those used by a number of other laboratories.
Several different immunodeficient mouse strains have
been used for xenografting, including nude, SCID, and
NOD-Rag. We have studied the latter, which have also
been examined by others [6–8, 10, 39, 40]. The death of
muscle fibers prior to studies of regeneration or engraft-
ment can be induced by cryodamage [6–8, 10, 39–41],
but anesthetics, such as bupivacaine, Ba2+, or toxins
such as notexin and cardiotoxin, have been used more
widely for this purpose and in some cases have been dir-
ectly compared [9, 57–60]. In our current experiments,
we chose to use cardiotoxin, with which we were already
familiar [33]. As in our previous studies of muscle injury
and regeneration [34], see also [61], we used 25 Gy ir-
radiation to prevent murine satellite cells from regener-
ating, rather than 18–20 Gy irradiation favored by
others [9, 10, 57, 60, 62]. To identify human myonuclei
and fibers, we used antibodies specific for human lamin
A/C and β-spectrin, as described [6–8, 10, 38–41]. Our
results show that this unique combination of reagents
and methods leads to engraftment of hMPCs and the
formation of fibers that are almost exclusively human in
origin.
Our approach also involves a novel use of iNMES to
promote the formation of human myofibers in the
mouse hindlimb. iNMES can promote both the engraft-
ment of myogenic cells and the recovery of muscle from
injury [25, 27–30, 63], but the mechanisms by which it
acts are still poorly understood. iNMES may modulate
the environment in the hindlimb, for example, by sup-
pressing inflammation, reducing proliferation of murine
fibroblasts, increasing angiogenesis, or promoting the in-
nervation of the engrafted tissue by murine motor neu-
rons. In clinical settings, electrotherapy has the potential
to produce a long-lasting reduction in inflammation
[64], though we are not aware of quantitative studies of
the effects of iNMES on inflammation of muscle. The
literature is also mute regarding the effects of electrical
stimulation on the development of fibrosis in developing,
damaged, or regenerating muscle. Electrical stimulation
has, however, been reported to increase angiogenesis in
muscle [25, 26] and regeneration of motor neurons
[65, 66], perhaps by increasing the levels of trophic fac-
tors such as vascular endothelial growth factor (VEGF)
and neurotrophins [67, 68]. Furthermore, iNMES can
promote the proliferation and differentiation of both
myoblasts and myotubes in vitro [22, 24, 69, 70]. Its
application in our in vivo studies may therefore in-
crease the number of hMPCs that survive following in-
jection, as well as their state of maturity at the time we
assay the grafts.
Despite the remarkable effects of iNMES, the grafts
that form with our procedures remain small. The largest
grafts formed by either LHCN or FSHD hMPCs contain
only ~10–30 % of the number of fibers of a mature TA
muscle in the mouse, and only a subset of these have di-
ameters similar to mature murine TA fibers. One pos-
sible explanation of the small sizes of the xenografts is
the massive loss of hMPCs within the first week follow-
ing injection into the hindlimb, as indicated by our bio-
luminescence imaging studies (Fig. 1), which occurs with
LHCN hMPCs at either dose of cells injected, with or
without iNMES. Although our luminometric data
Fig. 9 Xenografts generated with FSHD hMPCs. Xenografts were generated as for groups 2 and 3 (see Fig. 2), using FSHD hMPCs. a A graft
labeled with antibodies to desmin (red) and to human β-spectrin (green) shows many large muscle fibers of human origin that are up to 53 μm
in diameter. b Scattergram of counts of human muscle fibers in six xenografts treated with iNMES and six xenografts that remained untreated.
iNMES significantly increases the number of human fibers in the grafts formed by FSHD hMPCs (*p < 0.01)
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illustrating this acute cell loss show some variability, it is
clear that, regardless of treatment, >90 % of the bio-
luminescence signal emitted by the luciferase-expressing
hMPCs is lost within the first week in vivo.
Cell death caused by the failure of the myogenic
cells to attach to matrix or other physical structures in
the limb, known as anoikis [70], is likely to be a major
contributor to this loss. Consistent with this, co-
injection of human myoblasts with extracellular matrix
components can improve their survival, proliferation,
and migration, leading to a more successful engraft-
ment [71, 72]. Moreover, introduction of a fibrin gel,
which could provide additional adhesion sites, has
been reported to promote myoblast transplantation in
mice [73]. Organized three-dimensional matrices,
which have been studied in vitro [68, 69, 74–76], may
also be useful in providing adhesive surfaces and
thereby promoting survival and differentiation, to in-
crease the size of the grafts that we can generate in
vivo with the use of iNMES.
The proliferative ability of the hMPCs that survive en-
graftment may be limited, despite the benefits of iNMES.
Growth factors (IGF-1; [75, 77, 78]) or modulatory fac-
tors such as the binding site of the ActRIIB receptor,
which binds myostatin and other members of the TGF-β
family of polypeptide hormones [18], have been reported
to improve engraftment. Although they were tested
under different conditions than those used here, they
may also promote the growth and differentiation of the
grafts formed by hMPCs.
Yet another possibility is that the LHCN cells used in
our studies have only a limited ability to adhere, prolifer-
ate, and differentiate in vivo, perhaps because they have
been maintained in culture through many (>100) popu-
lation doublings. In this case, other immortalized lines
of hMPCs may engraft and form human muscle tissue in
mice more efficiently. Our initial observations on the ef-
ficiency of engraftment of FSHD cells (Fig. 9), which
have been through <30 passages and which generate xe-
nografts with approximately fivefold more muscle fibers,
is consistent with this. It is also conceivable that the
grafts were still growing at the time we harvested them
and that maintaining them for longer periods of time in
the mice will yield grafts of human muscle that are sig-
nificantly larger and better organized. We have been un-
able to identify Pax7-positive cells in the satellite cell
niche in our LHCN grafts, however, suggesting that fur-
ther growth may be slow, if it occurs at all. This agrees
with results of Mamchaoui et al. [39] but not with those
of several other laboratories [6, 7, 9, 40, 57, 79]. We are
currently pursuing experiments to address these ques-
tions, with the aim of increasing the size and improving
the morphology and physiology of the muscles generated
by our methods.
Conclusions
Although our research is still at an early stage, it has
nevertheless succeeded in generating xenografts of hu-
man muscle tissue in mice that are unique. These grafts
are formed from muscle precursor cells in a compart-
ment that is essentially devoid of murine muscle, in con-
trast to grafts of bundles of intact muscle fibers sewn
into pre-existing murine muscle, as recently described
[7]. Furthermore, the grafts consist of myofibers that are
fully differentiated and innervated by motor neurons.
Although we have not yet studied the muscles formed
by the grafts in isolation, our preliminary observations
indicate that they do indeed contract in response to elec-
trical stimulation. Perhaps most significantly, unlike
other studies of transplantation of human myoblasts into
mice, which generate hybrid fibers with both human and
murine myonuclei, the myofibers in the grafts we have
produced are essentially free of murine myonuclei and
are therefore largely human in origin. This indicates that
the methods we have used to eliminate the TA muscle of
the mouse and to prevent it from regenerating were
both successful and compatible with the formation of
human myofibers from injected hMPCs. Our results fur-
ther suggest that the methods we have developed will
also be useful for generating human muscle tissue in
mice from individuals with FSHD. We look forward to
using our methods not only to provide novel tools to
study the potentially unique properties of human skel-
etal muscle but also to develop new xenograft models
for human myopathies and muscular dystrophies.
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